ROBO2 and in situ carcinoma: We observed the downregulation of ROBO2 in the TOP-resistant A2780TR2 cell line, and previously we also observed the downregulation of ROBO2 in two CIS-resistant ovarian cancer cell lines [51], which suggests that the role of ROBO2 downregulation is in drug-resistance development.